跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 164 条关于
“Fosun Wanbang”
全部
164
临床试验
36
药物
61
机构
14
资讯
53
2个月前
Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang in Greater China Deal Worth Up to RMB 215 Million Upfront
8个月前
Sisram Medical's DAXXIFY Clears Final Regulatory Hurdle for China Market Launch
2年前
Fosun Pharma and MingMed Achieve Key Regulatory Milestones for Novel Therapies
去年
Fosun Pharma's Innovative Drug Receives Registration Acceptance in China
去年
Fosun Pharma Secures $645 Million Global Licensing Deal for Novel DPP-1 Inhibitor XH-S004
去年
Teva and Fosun Pharma Form Strategic Partnership for Novel Anti-PD1-IL2 Cancer Immunotherapy TEV-56278
4个月前
Arcera Life Sciences and Fosun Pharma Form Strategic Partnership to Bridge Chinese Innovation with Global Markets
5个月前
Fosun Pharma Receives NMPA Approval for Phase 1 Trial of HLX319 Biosimilar for Breast Cancer Treatment
去年
Fakeeh Care inks MoU with Fosun Pharma to develop cell, gene therapies
去年
Fosun Pharma Secures Exclusive Rights to Accro's TYK2/JAK1 Inhibitor AC-201 for Greater China in $21.8M Deal
第 1 页,共 6 页
上一页
下一页